THRN - Thorne HealthTech Inc Projected Price to Earnings

Graphic logo of Thorne Research (THRN)

The forward P/E ratio of Thorne HealthTech reflects investor expectations regarding profitability, while 15.90 captures the current state of this parameter. The operating model relies on contract laboratories and external IT services. Thorne HealthTech develops premium nutraceuticals and diagnostics for biohackers. A stable cash flow is ensured by high customer loyalty to personalized subscriptions, which sustain the business's momentum.

THRN - Thorne HealthTech, Inc. Future Price to Earnings Multiple over the range 07/04/2022 - 10/21/2023

Financial and market metric breakdowns for Thorne Research (THRN)

- stock quotes and analyst forecast:
Stock Price Thorne HealthTech, Inc.|THRN - Broker Consensus Forecast
- market capitalization statistics:
Market Valuation Thorne HealthTech Inc|THRN - Aggregate Business Value
- issuer book value statistics:
Book Value per Share Thorne HealthTech|THRN - Accounting Value of Company|Market Value to Book Value Ratio thorne.com|THRN - Company Assets
- debt and solvency information:
Debt to Equity Thorne HealthTech|THRN - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Thorne HealthTech|THRN - Company Aggregate Debt|Debts to Book Capitalization Thorne HealthTech Inc|THRN - Long-Term Debt|Company Current Liabilities Thorne HealthTech|Quick Ratio thorne.com
- earnings and market ratios statistics:
THRN - Final Profit|Projected Future Earnings Thorne HealthTech|THRN - Market Cap to Earnings|Forward P/E Multiple Thorne|THRN - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Thorne HealthTech Inc|THRN - Profit before payment of interest, taxes and amortization|Net earnings per share for the last 12 months Thorne HealthTech|THRN - Earnings per share for the last four quarters|Quarterly EPS earnings growth thorne.com|THRN - Earnings per share increase in current year|Expected earnings per share growth for next year Thorne HealthTech
Summary company analytics:Thorne HealthTech, Inc.
Signature product of Thorne HealthTech

From a conservative standpoint, analyzing the company's expected price-to-earnings ratio allows for an assessment of the current share price relative to projected net income, identifying whether the asset is overbought or undervalued. For Thorne HealthTech (THRN), which implements personalized biohacking based on DNA analysis, this indicator serves as a measure of how much the market currently prices in the future success of the transition to evidence-based medicine.

Competitors of Thorne HealthTech (THRN)

Forward P/E Multiple HIMS|Hinge Health, Inc. - Price to Future Earnings Ratio|Teladoc Inc. - Projected Price to Earnings|Market Cap to Future Earnings Ratio TALK (Talkspace Platform)|LifeMD Corp - Forward P/E Multiple|Future Price to Earnings Multiple AMWL (amwell.com)|mangorx.com (MGRX) - Future Price to Earnings|Projected Price to Earnings Ratio DarioHealth Corp (DRIO)|Future Price to Earnings VSee Health Inc|MNDR: Future Price to Earnings Multiple|Future Price to Earnings Accolade (ACCD)|biotricity.com - Price to Future Earnings Ratio|Forward P/E Multiple LYT (Lytus Technologies Holdings)|Ontrak Inc (OTRK) - Projected Price to Earnings Ratio|SHLT: Projected Price to Earnings